{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang J"],"funding":["American Cancer Society","NIDCR NIH HHS","NCI NIH HHS","NIGMS NIH HHS","NIH HHS","National Science Foundation"],"pagination":["486-495"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12797014"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["48(2)"],"pubmed_abstract":["<h4>Background</h4>Head and neck squamous cell carcinoma (HNSCC) is a malignancy with poor prognosis and survival. While epidermal growth factor receptor (EGFR) is a known driver of HNSCC, EGFR inhibitors show limited efficacy as monotherapies, suggesting that effective combination therapies are needed.<h4>Methods</h4>We performed GeCKO and Kinase CRISPR library screens to identify candidate knockouts that increase EGFR inhibitor sensitivity in resistant HNSCC cells. We validated a candidate using the CellTiter-Glo viability assay following RNA interference and investigated the mechanisms using apoptosis and cell cycle flow cytometry analysis.<h4>Results</h4>Kinase CRISPR library screens identified that PIK3C2A gene downregulation enhanced EGFR inhibitor sensitivity in resistant HNSCC cell"],"journal":["Head & neck"],"pubmed_title":["CRISPR Screens Identify PIK3C2A as a Novel Mediator of EGFR Inhibitor Resistance in Head and Neck Squamous Cell Carcinoma."],"pmcid":["PMC12797014"],"funding_grant_id":["F31 CA206341","DGE-1256260","R01 DE032699","T32GM145470","P30 CA046592","F31 CA206341-03","R01DE032699","T32 GM145470","P30-CA046592","U01 DE025184","U01DE025184"],"pubmed_authors":["Jiang H","Swiecicki P","Wang J","Chinn SB","Birkeland AC","Kulkarni A","Buchakjian M","Heft Neal M","Brenner JC","Gensterblum-Miller E","Ludwig ML","Michmerhuizen NL","Zhai J","Spector ME"],"additional_accession":[]},"is_claimable":false,"name":"CRISPR Screens Identify PIK3C2A as a Novel Mediator of EGFR Inhibitor Resistance in Head and Neck Squamous Cell Carcinoma.","description":"<h4>Background</h4>Head and neck squamous cell carcinoma (HNSCC) is a malignancy with poor prognosis and survival. While epidermal growth factor receptor (EGFR) is a known driver of HNSCC, EGFR inhibitors show limited efficacy as monotherapies, suggesting that effective combination therapies are needed.<h4>Methods</h4>We performed GeCKO and Kinase CRISPR library screens to identify candidate knockouts that increase EGFR inhibitor sensitivity in resistant HNSCC cells. We validated a candidate using the CellTiter-Glo viability assay following RNA interference and investigated the mechanisms using apoptosis and cell cycle flow cytometry analysis.<h4>Results</h4>Kinase CRISPR library screens identified that PIK3C2A gene downregulation enhanced EGFR inhibitor sensitivity in resistant HNSCC cell","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-06-06T15:23:22.301Z","creation":"2026-06-01T03:11:03.204Z"},"accession":"S-EPMC12797014","cross_references":{"pubmed":["40985049"],"doi":["10.1002/hed.70048"]}}